Galectin Therapeutics Inc (GALT) - Total Liabilities
Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has total liabilities worth $146.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Galectin Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Galectin Therapeutics Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Galectin Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Galectin Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Galectin Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cartesian Therapeutics Inc.
NASDAQ:RNAC
|
USA | $436.51 Million |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
USA | $12.99 Million |
|
Terra Santa Propriedades Agrícolas S.A.
SA:LAND3
|
Brazil | R$200.80 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
Jean Co Ltd
TW:2442
|
Taiwan | NT$15.58 Billion |
|
Lee Enterprises Incorporated
NASDAQ:LEE
|
USA | $621.80 Million |
|
Black Spade Acquisition III Co
NYSE:BIII
|
USA | $7.13 Million |
|
Becamex Infrastructure Development JSC
VN:IJC
|
Vietnam | ₫2.28 Trillion |
Liability Composition Analysis (2000–2025)
This chart breaks down Galectin Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GALT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galectin Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galectin Therapeutics Inc (2000–2025)
The table below shows the annual total liabilities of Galectin Therapeutics Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $145.73 Million | +20.87% |
| 2024-12-31 | $120.56 Million | +36.32% |
| 2023-12-31 | $88.44 Million | +65.38% |
| 2022-12-31 | $53.48 Million | +36.39% |
| 2021-12-31 | $39.21 Million | +625.19% |
| 2020-12-31 | $5.41 Million | +88.27% |
| 2019-12-31 | $2.87 Million | +36.24% |
| 2018-12-31 | $2.11 Million | -28.98% |
| 2017-12-31 | $2.97 Million | -21.48% |
| 2016-12-31 | $3.78 Million | +177.94% |
| 2015-12-31 | $1.36 Million | -20.14% |
| 2014-12-31 | $1.70 Million | -31.50% |
| 2013-12-31 | $2.49 Million | +51.22% |
| 2012-12-31 | $1.64 Million | -25.78% |
| 2011-12-31 | $2.21 Million | -72.29% |
| 2010-12-31 | $7.99 Million | +63.04% |
| 2009-12-31 | $4.90 Million | +317.99% |
| 2008-12-31 | $1.17 Million | -75.07% |
| 2007-12-31 | $4.71 Million | -26.30% |
| 2006-12-31 | $6.38 Million | +362.68% |
| 2005-12-31 | $1.38 Million | +37.31% |
| 2004-12-31 | $1.00 Million | +165.94% |
| 2003-12-31 | $377.91K | -43.32% |
| 2002-12-31 | $666.79K | +21.08% |
| 2001-12-31 | $550.70K | +205.95% |
| 2000-12-31 | $180.00K | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more